GlaxoSmithKline to provide unique child gene therapy


The world's first gene therapy treatment for children to be given regulatory approval has been authorised for sale by a British firm. GlaxoSmithKline was given permission by the European Commission to provide Strimvelis - the first ex-vivo stem cell gene therapy to treat patients with a very rare disease called ADA-SCID .



from Biotech News